Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 16 clinical trials
Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer

is studying how well breast duct endoscopy works in assessing cellular atypia (abnormal cells) in the breast ducts of women with a genetic risk for breast cancer.

immunohistochemistry
  • 0 views
  • 07 Nov, 2020
  • 1 location
Next Generation Sequencing NGS Monitors Minimal Residual Disease MRD in Allo-PBSCT Patients

Objective: to evaluate the value of high-throughput next generation gene sequencing (NGS) in the detection of minimal residual disease (MRD) and recurrence after allogeneic transplantation. Overview of study design. This study is a single-center, single-arm, prospective clinical trial designed to evaluate the significance of next generation gene sequencing (NGS) in …

  • 0 views
  • 23 Jan, 2021
  • 1 location
A Prospective Study of a Mosaic Embryo Transfer

This research is a prospective study in which the purpose is to investigate the clinical outcomes following the transfer of a mosaic embryo (presence of both chromosomally normal and abnormal

embryo transfer
single embryo transfers
  • 0 views
  • 26 Jan, 2021
  • 1 location
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma

responded to therapy (refractory). A T cell is a type of immune cell that can recognize and kill abnormal cells in the body. T cells are taken from the patient's blood and a modified gene is placed into

malignant glioma
measurable disease
x-rays
immunohistochemistry
platelet count
  • 60 views
  • 19 Feb, 2021
  • 2 locations
Venetoclax and ASTX727 for the Treatment of Relapsed Refractory or Newly Diagnosed Acute Myeloid Leukemia

. ASTX727 is the combination of a fixed dose of 2 drugs, cedazuridine and decitabine. Cedazuridine may slow down how fast decitabine is broken down by the body, and decitabine may block abnormal cells or

  • 0 views
  • 15 Mar, 2021
  • 1 location
Umbilical Cord Blood Transplant Cyclophosphamide Fludarabine and Total-Body Irradiation in Treating Patients With Hematologic Disease

hematologic disease. Giving chemotherapy, such as cyclophosphamide and fludarabine, and TBI before a donor umbilical cord blood transplant helps stop the growth of cancer and abnormal cells and helps stop the

chemotherapy regimen
blast crisis
chronic myeloid leukemia
carbon monoxide
white blood cells
  • 125 views
  • 11 Apr, 2021
  • 3 locations
JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis

) or evolved from other bone marrow disorders (secondary). JAK inhibitors are a class of drugs that may stop the growth of abnormal cells by blocking an enzyme needed for cell growth. Giving a JAK

ruxolitinib
janus kinase inhibitor
secondary myelofibrosis
total body irradiation
abnormal cells
  • 139 views
  • 03 Feb, 2021
  • 1 location
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm

plasmacytoid dendritic cell neoplasm that has returned after a period of improvement or has not responded to previous treatment. An immune cell is a type of blood cell that can recognize and kill abnormal

tyrosine
refractory acute myeloid leukemia (aml)
carbon monoxide
white blood cells
flow cytometry
  • 34 views
  • 05 Feb, 2021
  • 1 location
Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis

digestive tract. Treatment with chemotherapy can stop the growth of abnormal cells that produce this abnormal protein. Decrease in amyloid protein in the body improves the function of the affected organs

measurable disease
abnormal proteins
amyloid deposition
chemotherapy regimen
bone marrow procedure
  • 139 views
  • 25 Jan, 2021
  • 4 locations
ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas

this research study is evaluating the highest dose of ASTX727 that can be administered safely to recurrent/progressive non-enhancing IDH mutant gliomas patients.

  • 3 views
  • 25 Jan, 2021